Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 16.680-17.500 for the period, compared to the consensus EPS estimate of 17.230. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Price Performance

Shares of MEDP stock opened at $387.26 on Thursday. The business has a 50-day moving average of $471.41 and a 200 day moving average of $537.55. Medpace has a 1-year low of $284.10 and a 1-year high of $628.92. The stock has a market capitalization of $11.06 billion, a PE ratio of 24.84, a P/E/G ratio of 2.43 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. During the same quarter last year, the firm earned $3.67 EPS. The company’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts anticipate that Medpace will post 17.05 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on MEDP. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and cut their price objective for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a report on Friday, February 13th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Truist Financial reduced their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $486.67.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 20.50% of the stock is currently owned by insiders.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 results beat expectations — GAAP EPS $4.28 vs. ~$3.74 estimate and revenue $706.6M (up 26.5% y/y), showing strong profitability and margin expansion. Read More.
• Positive Sentiment: Backlog remains large (~$2.93B) and management maintained FY?2026 revenue and EPS guidance ranges, which supports medium?term revenue visibility. Read More.
• Neutral Sentiment: Market commentary flagged MEDP among pre?market laggards, amplifying volatility but not adding firm fundamentals. Read More.
• Neutral Sentiment: Analysts and coverage pieces note the mixed picture — strong quarter but questions about bookings recovery; consensus still expects ~17.05 EPS for FY?2026. Read More.
• Negative Sentiment: Bookings miss: net new business awards of ~$618M produced a net book?to?bill of ~0.88x in Q1, signaling bookings trailed recognized revenue and raising near?term growth concerns. Read More.
• Negative Sentiment: Leadership change: the company disclosed the planned retirement of President Jesse Geiger (effective May 31), creating short?term management uncertainty as the CEO temporarily re?assumes the role. Read More.
• Negative Sentiment: Multiple securities?fraud class actions and investor alerts were filed/announced by several law firms (SueWallSt, Portnoy, Rosen, Pomerantz, others), increasing legal and reputational risk and potential distraction/expense. Read More.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently bought and sold shares of MEDP. AQR Capital Management LLC grew its position in Medpace by 31.6% during the 4th quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after purchasing an additional 324,293 shares during the last quarter. Wasatch Advisors LP raised its holdings in Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after buying an additional 116,354 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after buying an additional 85,517 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Medpace by 20.7% during the third quarter. Bank of America Corp DE now owns 229,353 shares of the company’s stock valued at $117,924,000 after buying an additional 39,389 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.